J 2021

Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis

SINGH, A., Mohammad Salman HUSSAIN and B. ANTONY

Basic information

Original name

Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis

Authors

SINGH, A. (guarantor), Mohammad Salman HUSSAIN (356 India, belonging to the institution) and B. ANTONY

Edition

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, OXFORD, ELSEVIER SCI LTD, 2021, 1871-4021

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30202 Endocrinology and metabolism

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14110/21:00122062

Organization unit

Faculty of Medicine

DOI

UT WoS

000661873400025

Keywords in English

NAFLD; COVID-19; Mortality; Severity; Systematic review

Tags

Tags

International impact, Reviewed
Změněno: 9/8/2021 13:08, Mgr. Tereza Miškechová

Abstract

V originále

Background: Non-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable population that may be susceptible to more severe COVID-19. Moreover, not only the underlying NAFLD may influence the progression of COVID-19, but the COVID-19 may affect the clinical course of NAFLD as well. However, comprehensive evidence on clinical outcomes in patients with NAFLD is not well characterized. Objectives: To systematically review and meta-analysis the evidence on clinical outcomes in NAFLD patients with COVID-19. Methods: MEDLINE, EMBASE, and Cochrane Central were searched from inception through November 2020. Epidemiological studies assessing the clinical outcomes in COVID-19 patients with NAFLD were included. Newcastle-Ottawa Scale (NOS) was used to assess study quality. Generic inverse variance method using RevMan was used to determine the pooled estimates using the random-effects model. Results: Fourteen studies consisting of 1851 NAFLD patients, were included. Significant heterogeneity was observed among the studies, and studies were of moderate to high quality [mean, (range):8 (6, 8)]. For NAFLD patients, the adjusted odds ratio (aOR) for the severe COVID-19 was 2.60 (95%CI:2.24-3.02; p < 0.001) (studies,n:8), aOR for admission to ICU due to COVID-19 was 1.66 (95%CI:1.26-2.20; p < 0.001) (studies,n:2), and aOR for mortality for was 1.01 (95%CI:0.65-1.58; p 1/4 0.96) (studies,n:2). Conclusions: An increased risk of severe COVID-19 infection and admission to ICU due to COVID-19 with no difference in mortality was observed between NAFLD and non-NAFLD patients. Future studies should include the mortality outcome to conclusively elucidate the impact of NAFLD in patients with COVID-19. (C) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.